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ABSTRACT
Introduction: The Chasing COVID Cohort (C3) study is a US-based, geographically and
socio-demographically diverse sample of adults (18 and older) enrolled into a prospective cohort
study during the upswing of the U.S. COVID-19 pandemic.
Methods: We used internet-based strategies to enroll C3 participants beginning March 28th,
2020. Following baseline questionnaire completion, study participants will be contacted monthly
(for 6 months) to complete assessments of engagement in non-pharmaceutical interventions
(e.g., use of cloth masks, avoiding large gatherings); COVID-19 symptoms; SARS/COV2 testing
and diagnosis; hospitalizations; healthcare access; and uptake of health messaging. Dried
blood spot (DBS) specimens will be collected at the first follow-up assessment (last week of
April 2020) and at month 3 (last week of June 2020) and stored until a validated serologic test is
available.
Results: As of April 20, 2020, the number of people that completed the baseline survey and
provided contact information for follow-up was 7,070. Participants resided in all 50 US states,
the District of Columbia, Puerto Rico, and Guam. At least 24% of participants were frontline
workers (healthcare and other essential workers). Twenty-three percent (23%) were 60+ years,
24% were Black or Hispanic, 52% were men, and 52% were currently employed. Nearly 20%
reported recent COVID-like symptoms (cough, fever or shortness of breath) and a high
proportion reported engaging in non-pharmaceutical interventions that reduce SARS/COV2
spread (93% avoided groups >20, 58% wore masks; 73% quarantined). More than half (54%)
had higher risk for severe COVID-19 illness should they become infected with SARS/COV2
based on age, underlying health conditions (e.g., chronic lung disease), or daily smoking.
Discussion: A geographically and socio-demographically diverse group of participants was
rapidly enrolled in the C3 during the upswing of the SARS/COV2 pandemic. Strengths of the C3
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include the potential for direct observation of, and risk factors for, seroconversion and incident
COVID disease (among those with or without antibodies to SARS/COV2) in areas of active
transmission.
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INTRODUCTION
The Coronavirus Disease 2019 (COVID-19) pandemic has dramatically transformed life
across the entire United States, resulting in medical and economic challenges and threats for
many households and communities. The earliest research efforts have focused on
understanding the clinical course of COVID-19 and the most effective ways of treating people
with severe symptoms or illness. As the pandemic progresses, however, we must also
investigate COVID-19’s evolving epidemiology and the impact of non-pharmaceutical
interventions (NPIs), such as physical distancing, health messaging, and testing. Researchers
and public health practitioners have called for cohort studies to describe the community attack
rate, as well as how attack rates are influenced by different approaches to NPI implementation.1
Internet-based strategies, which facilitate rapid recruitment of large and diverse samples, can be
leveraged to understand and inform this swiftly changing and protracted public health crisis.2,3
In response to the COVID-19 pandemic the CUNY Institute for Implementation Science
in Population Health (ISPH) launched the Communities, Households and SARS/COV-2
Epidemiology (CHASING) COVID Cohort “C3” study on March 28, 2020. We sought to recruit an
online prospective cohort of 7,500 adults (18 years or older) in the United States (US) and US
territories in order to rapidly contribute to our understanding of the spread and impact of the
SARS/COV2 pandemic within households and communities. In a prospective cohort study, we
will assess the impact of implementing, and relaxing, NPIs on SARS/COV2 clinical outcomes
and psychosocial outcomes such as mental health, social support, and interpersonal violence.
METHODS
We aimed to rapidly enroll a geographically and socio-demographically diverse sample
of adult participants residing in the US and US territories. We applied internet-based strategies
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that have been demonstrated to be effective for recruiting and following large and
geographically diverse online cohorts.2–4
Cohort Eligibility and Recruitment
Persons aged 18 years and above who resided in the US or US territories were eligible
to join the study. Study participants were recruited via social media platforms (e.g., Facebook,
Instagram, and Scruff) or via referral to the study. Anyone with knowledge of the study was
allowed to invite others to participate. By tapping into personal networks of participants, we
aimed to improve recruitment of persons >59 years of age, who may not be as active on social
media as younger persons and thus rely more on snowball sampling methods. The study was
promoted as a way for participants to contribute to understanding the COVID-19 pandemic.
Facebook and Instagram advertisements were developed in English and Spanish and were
geographically targeted to people currently residing in the US and US territories who were 18 or
older.
The C3 had a targeted sample size of 7,500 participants. Study staff actively monitored
cohort demographics and adjusted advertisement strategies as needed to recruit a more
geographically and socio-demographically diverse sample. The advertisement strategies were
adaptive based on the profile of participants enrolled as of a given date. For example, strategies
could shift to recruit older persons if that demographic was not well-represented.
Potential participants were directed to an enrollment survey (hosted by Qualtrics) in their
web browser on a computer or mobile device.5 The consent form described the study, monthly
follow-up assessments, and future study opportunities, including the possibility to receive a
SARS/COV2 serologic test as part of the study. The consent form also described the incentive
schedule: a drawing for $100 for the baseline survey (with 20 winners) and gift cards ranging
from $5-30 for all participants for completion of subsequent surveys and antibody testing.
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Enrollment and baseline assessment
Enrollment for C3 began on March 28, 2020, at which point there were 122,000
documented COVID-19 cases and 2,200 COVID-19 deaths reported in the US.64 Enrollment
ended on April 20, 2020, when there were 783,000 persons diagnosed with SARS/COV2,
including 42,000 deaths in the
U.S. (Figure 1).6
Individuals who provided
informed consent were then
screened for eligibility via the
Qualtrics survey. Eligible and
consenting individuals were asked
to provide an email address for
future follow-up assessments.
Measures included on the baseline questionnaire were derived from previously published
research (e.g., Together 50002, BRFSS, and H1N1 influenza studies7,8) and from other
researchers who had developed surveys for understanding COVID-19 (e.g., Canadian Institutes
of Health Research7 and Food Access and Food Security during COVID-199). Measures were
also developed de novo i n response to the novel pandemic. We deployed a second version of
the baseline questionnaire on April 9, 2020, which added questions to capture healthcare and
other essential worker status. The surveys are available on the C3 webpage
(https://cunyisph.org/chasing-covid/).
Follow-up assessments
Questionnaires. Following the baseline assessment, C3 participants will be surveyed
monthly for 6-months (until September, 2020). The follow-up assessments will gather data on
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symptoms, testing, hospitalizations and other time-varying factors (e.g., NPI uptake and
relaxation) (see Table 1 for survey realms).
Specimen collection. At the first follow-up assessment (end of April, 2020) and the third
follow-up assessment (end of June, 2020), participants will be asked to self-collect a specimen
for serologic testing. Participants will be mailed dried blood spot (DBS) self-sampling kits. Using
the provided lancet, they will prick the side of their finger and provide a sample of blood on the
provided card. To facilitate
self-sampling procedures, all
participants will receive printed
instructions demonstrating
procedures for DBS collection
and instructions to contact the
study team, if they have
questions.10 DBS cards will be
returned via US Postal Service
(self-addressed, stamped
envelope containing EBF Foil
biohazard bag™) to the C3 study
laboratory (Molecular Testing
Labs)11, where they will be
banked at -80ºC for future
serologic testing for IgM and IgG
antibodies to SARS/COV2 via a
suitable validated assay. We will monitor the emerging pipeline of serology test systems.
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Participants who do not submit a DBS card at the end of Month 1 will be sent a reminder and
will be allowed to submit it at any time during follow-up. Participants will receive $20 upon
returning a valid specimen to the study laboratory.

Daily symptom tracking. Monthly assessments are supplemented by voluntary daily
symptom tracking via an innovative COVID-19 symptom tracker12 that we have deployed in our
cohort. The Coronavirus Pandemic Epidemiology (COPE) consortium has developed the COVID
Symptom Tracker app, downloadable for free in the Apple and Android App Stores, which
enables individuals to self-report information on COVID-19 exposure and infections. On first
use, the app queries location, age, and core risk factors and comorbidities. Daily prompts query
for updates on interim symptoms, health care visits, and COVID-19 testing results. The C3 Study
joined the COPE consortium on April 6th, allowing our cohort members who use the app to
consent to share their data with us so that it can be linked to the larger C3 cohort data. Consent
to merge data from the symptom tracker app with other C3 data is being solicited at the Month 1
follow-up assessment.
Outcomes
Incidence of SARS/COV2 i nfection. T
 he cumulative incidence of SARS/COV2 infection at
the end of Month 1 (~end of April, 2020) and Month 3 (~end of June, 2020) will be defined as
the proportion of persons at each time point with SARS/COV2 infection as confirmed by
serologic testing: IgM and/or IgG positive. For persons testing positive at Month 1, we will
assume infection occurred at the midpoint between 5 days before the county’s first reported
SARS/COV2 diagnosis and the date of the serologic test, unless we can assign a more
accurate date based on reported symptoms and/or presence of IgM/IgG. For those who test
negative at Month 1 and positive at Month 3, we will assume infection occurred at the midpoint
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between the two tests (if no symptoms) or 5 days before a documented report of onset of
COVID-like symptoms.
Asymptomatic SARS/COV2 infection. Asymptomatic infection will be defined as a positive
SARS/COV2 serologic test, with no documented report of COVID-like symptoms from prior C3
interviews or from the COVID-19 symptom tracker app. The proportion with asymptomatic
infection among persons with a positive SARS/COV2 serologic test will then be calculated as
the number with asymptomatic infection divided by the total number with a positive serologic
test. We will stratify our estimates of the proportion with asymptomatic infection by whether the
seroconversion occurred prior to month 1 or whether seroconversion was observed in the cohort
between Months 1 and 3 among those with a documented negative serologic test at Month 1.
Confirmed and possible COVID-19 disease at or prior to baseline. For SARS/COV2
seropositive persons, we will define confirmed prior COVID-19 as a self-report of symptoms
consistent with COVID-19 on our symptom screener in the two weeks prior to baseline, with a
date of disease onset estimated as one week prior to baseline. Those reporting COVID-19
symptoms without a serologic test will be considered possible cases of prior COVID-19.
Confirmed incident COVID-19 d
 isease after serologic testing. For analyses to assess
subsequent disease after Month 1, incident COVID-19 disease will be defined as development
of new COVID-like symptoms >7 days after the first (positive or negative) SARS/COV2 serologic
test result.13 We will count new COVID-19 disease, including a self-report of COVID-like
symptoms, COVID-19 diagnosis or hospitalization on the C3 questionnaire or via the COVID-19
symptom tracker app. Severe COVID-19 disease will be defined as having been hospitalized for
COVID-like symptoms.
Other outcomes. We will examine secondary outcomes such as: anxiety symptoms
(Generalized Anxiety Disorder-7 [GAD-7] 7-item scale]14), and depressive symptoms (Patient
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Health Questionnaire-2 [PHQ-2]15). We will also measure and describe the prevalence of food
insecurity9, substance use16,17, unhealthy drinking (Alcohol Use Disorders Identification Test
[AUDIT-C])[18, and intimate partner violence (IPV).
Exposures
NPI uptake in the C3 cohort. We will examine specific NPI uptake among C3 cohort
participants over time, and also calculate NPI uptake by creating an index. The index is a
summative score of responses to survey questions about engagement in NPI actions in the two
weeks prior to the survey. Each affirmative or neutral action is weighted 1 and each negative
response 0, so that a higher index value indicates greater NPI uptake/engagement.
State level NPI implementation. We and others have compiled living databases of
state-level implementation, and relaxing of NPIs, which document the type and date of NPI
implementation (e.g., school closings, restaurant closings, stay at home order, cloth masks),
who is covered (older persons, non-essential workers), as well as when specific NPIs are
relaxed. We will characterize NPI implementation according to indices of stringency developed
by others.19
County-level physical distancing. Stay-at-home orders and other measures have greatly
reduced population mobility in many areas.20 We will operationalize physical distancing using a
proxy—changes in mobility at the county level relative to the timing of first cases and deaths in
each county—to classify counties as having achieved physical distancing early or late and to
assess the influence of relaxing physical distancing measures (relative to nadir). We will use
county-level data on mobility, updated daily, from Descartes Labs (posted on GitHub)21. These
data include mobility calculated using GPS data from ‘a collection of mobile devices reporting
consistently throughout’ each day.22 The maximum distance moved in kilometers is calculated
daily for each person, and aggregated up to the county level median (or other aggregate
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metric). We will use the following metrics: 1. M50 - the median of the max-distance mobility for
all samples in each county; and 2. M50I (m50 index) - the percent of normal M50 in the region,
with normal M50 defined during Feb 17, 2020 to March 7, 2020. M50, and to a lesser degree
M50I, will be highly influenced by the proximity/density of resources (e.g., supermarkets).
Planned analyses. We will
integrate time-updated publicly
available county-level data on
mobility22, SARS/COV2 diagnoses,
and COVID-19 deaths23 with our
longitudinal C3 cohort data to
determine the impact of NPI
implementation on SARS/COV2
outcomes. Among SARS/COV2
seropositive individuals, we will
estimate the proportion with asymptomatic and mild disease using their previously reported data
on symptoms consistent with COVID-19, weighted to the US adult population using age, sex,
and race/ethnicity stratification. To assess whether seropositivity for SARS/COV2 is protective
against new disease, we will compare the incidence of COVID-like disease (any and severe)
among persons previously identified as seropositive to that of persons previously identified as
seronegative, geographically matched within areas where SARS/COV2 transmission remains
active.
Data management
All data were imported and cleaned in R and SAS (V9.4). Data were geocoded based on
a self-reported ZIP code. Maps were created in ArcGIS 10.7.
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Ethical Approval
The C3 study protocol was approved by the Institutional Review Board at the City
University of New York (CUNY) Graduate School for Public Health and Health Policy.
RESULTS
Cohort Eligibility and Recruitment
Among the N=8,711 participants who were eligible, 82% (N = 7,125) completed the
survey, and 81% (7,070) left an email address for future study-follow-up (Figure 2).
Baseline Characteristics of C3  Stratified
by Age Characteristics
The final cohort of 7,070 was
geographically diverse (Figure 3), with
participants from all 50 states, the
District of Columbia, Puerto Rico and
Guam. The median age of participants
was 42 years (interquartile range: 31,
58); 61% were aged 18-49 (including
5% <21 years (N=345)), 16% were aged 50-59, and 23% were aged 60 years or older (Table 1).
Just over half (51%) were male, 14% were Hispanic, 11% black non-Hispanic, 5% Asian or
Pacific Islander, and 67% white non-Hispanic. A majority were currently employed (53%), 18%
were retired, 16% were out of work, and 9% were students.
More than half (54%) were at increased risk for COVID-19 illness should they become
infected with SARS/COV2 on the basis of age (60+), reporting an underlying health condition
(chronic lung disease, asthma (current), type 2 diabetes, serious heart condition, kidney
disease, or an immunocompromised status), or daily smoking (Table 2). The proportion of
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persons with an underlying health
condition increased with age
category (28% among 18-49 year
olds and 44% among 60+), and
the proportion of daily smokers
decreased with increasing age
category (20% and 11%,
respectively).
Among 5,403 participants
that completed the updated
version of the baseline
assessment that included
questions on essential
employment (participants could
select more than one employment
category), 24% reported being a
frontline worker (healthcare or
other essential workers) (Table 2,
Figure 1). By employment
category, 9% were healthcare
workers, 5% were healthcare
workers who screened or cared for
COVID-19 patients, 11% were in
delivery services (e.g., food) and
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4% were in transportation (e.g., taxis). The proportion of persons employed in frontline work
decreased with increasing category of age.
NPI / Physical Distancing Behaviors Stratified by Age Categories
A high proportion of participants reported avoiding large groups with >20 people in the
past two weeks and avoiding handshakes or hugs (93% and 92%, respectively) (Table 3).
Nearly half (49%) reported working from home. A majority reported wearing gloves (56%) and
masks (58%), and these proportions significantly increased with age (54% of 18-49 year olds
wore gloves versus 61% of 60+, and 54% of 18-49 year olds wore masks versus 68% of 60+, p
for chi-square: <0.001 for each comparison). Almost one in six (15%) participants reported
stockpiling personal protective equipment and 41% reported stockpiling food. The proportion of
participants who reported stockpiling decreased significantly with increasing age categories
(17% of 18-49 year olds stockpiled PPE versus 13% of 60+, and 47% of 18-49 year olds
stockpiled food versus 31% of 60+, p<0.001 for each comparison).
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COVID-19 symptoms and care outcomes
One in five (20% or N = 1,436) reported any COVID-like symptoms prior to C3 enrollment
(cough, fever or shortness of breath) and this decreased significantly with age (23% versus 13%
among 18-49 and 60+ year olds, respectively and p<0.001) (Table 3). The most common
symptoms reported were new cough (12%) followed by shortness of breath (9%) and fever
(7%).
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Among the 20% of participants reporting COVID-like symptoms (N = 1,436), 39% (N =
555) said they called or saw a physician/healthcare professional and 12% (N = 166) were
hospitalized (Table 4). Compared to participants at lower risk for COVID-19 illness, participants
with higher risk for severe COVID-19 illness were more likely to report seeing a physician or
hospitalization (28% versus 46% and 2% versus 18%, respectively and p <0.001 for each
comparison). Among all participants, 5% (N = 368) reported being tested for COVID-19 and 3%
(N = 191) reported receiving a COVID-19 diagnosis. Participants at h
 igher risk for COVID-19
illness were significantly more likely to report testing or receiving a diagnosis than participants at
lower risk for severe COVID-19 illness (testing: 7% versus 3% and diagnosis: 4% versus 1%,
respectively and p<0.001 for each comparison).
DISCUSSION
The C3 study of 7,070 persons from all 50 US states, the District of Columbia, Puerto
Rico and Guam was rapidly established in the middle of the SARS/COV2 upswing in the US.
The C3 cohort is geographically and socio-demographically diverse, and includes participants
from many active hotspots during the recruitment period (March 28-April 20, 2020), as well as
frontline health care workers and other essential employees, and individuals who are vulnerable
to severe outcomes associated with SARS/COV2 infection.
At the baseline assessment, nearly one in five reported having had recent COVID-like
symptoms. Among those reporting COVID-like symptoms, 38% reported seeing a health care
provider and 12% reported being hospitalized. A small proportion of C3 participants reported
being tested for or diagnosed with SARS/COV2 (5% and 3%, respectively), and participants
with elevated risk for COVID-19 illness were more likely to report seeking care, hospitalization,
and testing than participants without elevated risk. Limitations of serological assays
notwithstanding, recent cross-sectional serosurveys done prior to the relaxing of physical
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distancing have reported seroprevalence estimates ranging from 3% in CA to 21% in NYC.24–26
Many in the C3 cohort are likely to have serologic evidence of prior SARS/COV2 infection as of
the Month 1 follow-up assessment. Those that are seronegative at Month 1 may be at high risk
for seroconversion between Months 1 and 3, given ongoing transmission in many areas, and
the expectation of physical distancing measures being relaxed in the coming months. When this
occurs, many areas will also be implementing enhanced testing, contact tracing, and
quarantine. The C3 Study has the potential to monitor and assess the uptake and impact of
these key strategies that are part of the public health response to control and mitigate the
SARS/COV2 pandemic in the U.S.
Strengths of the C3 study include its prospective (vs. cross-sectional) design, allowing
direct observation of seroconversions and incident COVID disease among those who were
unexposed and/or disease free. The longitudinal design also allows prospective estimation of
the incidence of COVID disease among those with antibodies to SARS/COV2, allowing a rapid
assessment -- in the midst of a pandemic -- of the extent to which SARS/COV2 antibodies offer
short-term protection against subsequent disease. Prospective studies, which by definition
follow the same individuals forward in time, are complementary to and offer some strengths over
cross sectional studies, especially in the context of rapidly evolving emergencies and the
associated public health response. While repeat cross-sectional surveys are valuable in a
pandemic, including their ability to assess trends in many important outcomes, they cannot
assess what factors may influence change over time in an individual. Cross-sectional studies
also by definition will exclude persons who are in the hospital or who have died.
We are using assessment strategies designed to minimize their assessment effects, as
well as objective biological indicators. Studies requiring human contact can cause participants to
under-report sensitive health behaviors and to adopt behaviors that make them less
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representative of the populations from which they were drawn. Studies involving high levels of
contact may induce behavior change by repeatedly engaging participants outside of their natural
context, artificially biasing results27,28 and reducing generalizability.29
The C3 study has limitations worth noting, as they inform what can and cannot be
assessed. First, C3 will be unable to provide representative estimates of prevalence and
incidence. Second, we will underestimate hospitalizations and are unable to capture deaths due
to COVID or other causes. Most research studies, including ours, deployed in the middle of a
pandemic will, by definition, produce some biased estimates since they will not include
information on persons who died from COVID, were hospitalized with COVID prior to or during
recruitment, or were too sick to participate in a research study at the time of recruitment. From
published studies, we will assess bias in our estimates due to these factors and adjust them
accordingly. Third, we will be unable to conduct state or county specific analyses, except for a
few localities with high participation (e.g., New York and California). Finally, we do not yet know
the retention rate or the acceptance rate for specimen collection. However, participants may be
more motivated to participate in follow-up, given the active threat and novelty of the COVID-19
pandemic and its ongoing impact on individuals and communities.
We considered the strengths and weaknesses of several different study designs and
methodologic features when designing and launching the C3. Ultimately, we chose a design that
prioritized our ability to rapidly answer key epidemiologic questions and enroll a geographically
and socio-demographically diverse sample of individuals. We considered whether a probability
sample of households with a telephone phone interview should be leveraged, given the potential
to use a known sampling frame which would facilitate estimates that may be more population
representative. However, given the need for rapid information and knowledge generation, we
chose to recruit participants from online settings, and enrolled >7,000 people in 3 weeks.
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Although our sample is not representative of the entire US population, it is geographically
representative and socio-demographically diverse. Our study will complement other efforts to
address similar research questions, such as the NIH’s planned serosurvey.30 Indeed, it will be
important to assess if online vs. conventional recruitment methods reach similar conclusions.
Our approach employs protocols for overcoming common pitfalls of fully online studies
(e.g., repeat/duplicate participation). Our online, volunteer recruitment approach allows us to
sample individuals who may not be reached by traditional telephone recruitment approaches,
which can have very low response rates. As part of our enrollment procedures, we record IP
address, email addresses, participant contact information, and require participants to have valid
US mailing addresses (required to receive an at-home SARS/COV2 specimen collection kit).
Participants will be “known” to the research team (name, email, address), thus averting some of
the traditional shortcomings of online-only studies (particularly anonymous, cross-sectional
online studies).
Data sharing
We plan to rapidly produce manuscripts, which will be simultaneously submitted to
MedRxiv[75] and leading scientific journals for peer review. To increase the impact of our work,
we will also post a deidentified, HIPAA compliant, public use version of our baseline and
follow-up data on GitHub.[76] Data will be presented as flat text files (CSV) formatted for
compatibility with the New York Times county-level longitudinal case load dataset[3], including
date, county, state, and fips code. A GitHub Actions script will perform weekly updates of the
repository and its associated GitHub Pages site, automatically incorporating all new
submissions from the previous week. Finally, we will provide direct feedback to our cohort and
other stakeholders who have signed up for updates via our C3 newsletter.31
Conclusion
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A geographically and socio-demographically diverse group of participants was rapidly
enrolled in the C3 during the upswing of the SARS/COV2 pandemic. Strengths of the C3 include
the potential for direct observation of, and risk factors for, seroconversions and incident COVID
disease (among those with or without antibodies to SARS/COV2) in areas of active
transmission. The C3 Study has the potential to monitor and assess the uptake and impact of
the public health response to control and mitigate the SARS/COV2 pandemic in the US.
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